Regulatory News: Lysogene (Paris:LYS) (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced the appointment of Côme de La Tour
Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Lysogene Reports First Half 2022 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.